Myrobalan Therapeutics

Myrobalan Therapeutics Appoints Robin Kleiman Ph.D., as Chief Scientific Officer

Dr. Kleiman brings more than 25 years of neuroscience drug discovery leadership, including the discovery and development of multiple novel clinical candidates Press Releae – October 31, 2024 – MEDFORD, Mass. – Myrobalan Therapeutics, a biotechnology company developing novel oral small-molecule therapies to repair damage and restore brain function in high-unmet need central nervous system (CNS) conditions, announces the appointment of Robin Kleiman, Ph.D., as … Continue reading Myrobalan Therapeutics Appoints Robin Kleiman Ph.D., as Chief Scientific Officer